Charles River Laboratories International Past Earnings Performance
Past criteria checks 2/6
Charles River Laboratories International has been growing earnings at an average annual rate of 17.4%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 12.9% per year. Charles River Laboratories International's return on equity is 13.1%, and it has net margins of 11.5%.
Key information
17.4%
Earnings growth rate
16.2%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 12.9% |
| Return on equity | 13.1% |
| Net Margin | 11.5% |
| Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Charles River Laboratories International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Dec 23 | 4,129 | 475 | 736 | 0 |
| 30 Sep 23 | 4,216 | 475 | 755 | 0 |
| 01 Jul 23 | 4,178 | 484 | 760 | 0 |
| 01 Apr 23 | 4,092 | 496 | 688 | 0 |
| 31 Dec 22 | 3,976 | 486 | 655 | 0 |
| 24 Sep 22 | 3,781 | 436 | 585 | 0 |
| 25 Jun 22 | 3,688 | 443 | 549 | 0 |
| 26 Mar 22 | 3,630 | 422 | 578 | 0 |
| 25 Dec 21 | 3,540 | 391 | 578 | 0 |
| 25 Sep 21 | 3,426 | 397 | 582 | 0 |
| 26 Jun 21 | 3,273 | 396 | 566 | 0 |
| 27 Mar 21 | 3,041 | 375 | 528 | 0 |
| 26 Dec 20 | 2,924 | 364 | 523 | 0 |
| 26 Sep 20 | 2,824 | 301 | 501 | 0 |
| 27 Jun 20 | 2,749 | 271 | 502 | 0 |
| 28 Mar 20 | 2,724 | 248 | 520 | 0 |
| 28 Dec 19 | 2,621 | 252 | 488 | 0 |
| 28 Sep 19 | 2,532 | 231 | 493 | 0 |
| 29 Jun 19 | 2,449 | 219 | 473 | 0 |
| 30 Mar 19 | 2,377 | 227 | 456 | 0 |
| 29 Dec 18 | 2,266 | 225 | 436 | 0 |
| 29 Sep 18 | 2,143 | 135 | 419 | 0 |
| 30 Jun 18 | 2,022 | 128 | 401 | 0 |
| 31 Mar 18 | 1,906 | 129 | 377 | 0 |
| 30 Dec 17 | 1,858 | 123 | 367 | 0 |
| 30 Sep 17 | 1,846 | 198 | 370 | 0 |
| 01 Jul 17 | 1,807 | 183 | 363 | 0 |
| 01 Apr 17 | 1,772 | 164 | 357 | 0 |
| 31 Dec 16 | 1,681 | 154 | 343 | 0 |
| 24 Sep 16 | 1,568 | 143 | 325 | 0 |
| 25 Jun 16 | 1,492 | 143 | 309 | 0 |
| 26 Mar 16 | 1,398 | 156 | 288 | 0 |
| 26 Dec 15 | 1,363 | 150 | 279 | 0 |
| 26 Sep 15 | 1,339 | 146 | 277 | 0 |
| 27 Jun 15 | 1,317 | 140 | 276 | 0 |
| 28 Mar 15 | 1,319 | 127 | 274 | 0 |
| 27 Dec 14 | 1,298 | 128 | 258 | 0 |
| 27 Sep 14 | 1,257 | 120 | 248 | 0 |
| 28 Jun 14 | 1,222 | 119 | 236 | 0 |
| 29 Mar 14 | 1,174 | 111 | 226 | 0 |
| 28 Dec 13 | 1,166 | 104 | 226 | 0 |
| 28 Sep 13 | 1,156 | 108 | 213 | 0 |
| 29 Jun 13 | 1,143 | 99 | 210 | 0 |
Quality Earnings: RV6 has high quality earnings.
Growing Profit Margin: RV6's current net profit margins (11.5%) are lower than last year (12.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RV6's earnings have grown by 17.4% per year over the past 5 years.
Accelerating Growth: RV6's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: RV6 had negative earnings growth (-2.3%) over the past year, making it difficult to compare to the Life Sciences industry average (6.5%).
Return on Equity
High ROE: RV6's Return on Equity (13.1%) is considered low.